Sichuan Huiyu Pharmaceutical Co Ltd (688553) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Sichuan Huiyu Pharmaceutical Co Ltd ¥3.38, price ¥11.85, upside -71.5%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
59‑month range ¥6.30 – ¥24.60 · fair‑value band ¥3.23 – ¥3.53 · the ¥11.85 price screens above the ¥3.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Sichuan Huiyu Pharmaceutical Co in your weekly email
Every Wednesday you see whether Sichuan Huiyu Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally.
Show more
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. It also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, panosetron hydrochloride, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, thiotepa, teicoplanin, epirubicin hydrochloride, methotrexate, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorportaed in 2010 and is headquartered in Neijiang, China.
Stock analysis
Sichuan Huiyu Pharmaceutical Co Ltd (688553) currently trades at ¥11.85, while our model-based Fair Value estimate is ¥3.38, 71.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥4.43 per share, and 0 of the 4 models we run sit above the ¥11.85 price.
Bear case: the Asset-Based group reads lowest at ¥4.02, and 4 of the 4 models stay below the price. Evidence for this calculation is medium.
Scenario range: ¥3.23 (bear) to ¥3.53 (bull), the price of ¥11.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Sichuan Huiyu Pharmaceutical Co Ltd reported revenue of 998M CNY in FY2025 versus 1.8B CNY in FY2021, a compound −14.0%/yr. Reported net income was −24.2M CNY in FY2025.
Key figures
Market cap 8.0B CNY (≈ $1.2B) · P/E ratio 49.4 · P/S ratio 7.33 · EPS (TTM) ¥0.2400 · Dividend yield 1.1% · Net margin −2.4% · Return on equity 3.0% · Return on assets (EBIT) 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −71%, 688553 screens richer than that median.
Fair Value models
Bear ¥3.23Fair Value ¥3.38Bull ¥3.53
Price ¥11.85 · Upside -71.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.0814 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.19/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+70.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
29.2% (2020) → −6.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Sichuan Huiyu Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 571 stocks
Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−71.5% · Bottom 25%
Profitability
Return on equity (TTM)3.0% · Below median
Return on assets0.8% · Below median
Net margin (TTM)10.3% · Above median
Operating margin (TTM)2.1% · Below median
Growth and dividend
Revenue growth32.0% · Top 25%
Dividend yield (TTM)1.1% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)49.4× · Priciest 25%
P/B2.14× · Pricier than median
P/S (TTM)7.33× · Priciest 25%
EV/EBITDA36.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)100· sector 25
PAST (return on equity)12· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)23· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sichuan Huiyu Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/688553
Frequently asked questions
Is Sichuan Huiyu Pharmaceutical Co Ltd (688553) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ¥3.38 versus a price of ¥11.85, about −71% upside (overvalued).
What is the fair value of 688553?
Our model-based fair value for Sichuan Huiyu Pharmaceutical Co Ltd is ¥3.38 (as of Oct 1, 2026), built from audited fundamentals. The current price: ¥11.85.
What is the quality score of 688553?
Sichuan Huiyu Pharmaceutical Co Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
Our model-based price target is the fair value of ¥3.38 (as of Oct 1, 2026) from 4 valuation models. Cautious scenario ¥3.23, optimistic scenario ¥3.53. It is a calculation from audited fundamentals, not an analyst target.
What is the Sichuan Huiyu Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥3.38, about −71% upside versus a price of ¥11.85 (overvalued). Cautious scenario ¥3.23, optimistic scenario ¥3.53. The calculation is refreshed regularly with new filings.
What is the revenue of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
Sichuan Huiyu Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 1.1B CNY (latest available figure, as of Oct 1, 2026).
Does Sichuan Huiyu Pharmaceutical Co Ltd pay a dividend?
Sichuan Huiyu Pharmaceutical Co Ltd currently shows a dividend yield of about 1.14% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sichuan Huiyu Pharmaceutical Co Ltd it is ¥3.38 per share (as of Oct 1, 2026), against a price of ¥11.85. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Sichuan Huiyu Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 688553 trades above its calculated fair value: price ¥11.85, fair value ¥3.38, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688553?
No. The price is what the market pays today (¥11.85); the fair value is what the company's own numbers justify (¥3.38). For Sichuan Huiyu Pharmaceutical Co Ltd the two are ¥8.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sichuan Huiyu Pharmaceutical Co Ltd worth?
The market values Sichuan Huiyu Pharmaceutical Co Ltd at about 8.0B CNY (market capitalisation, as of Oct 1, 2026). Per share that is ¥11.85; our models calculate a fair value of ¥3.38 per share.
What do the bullish and bearish scenarios say about 688553?
Our models span a range for Sichuan Huiyu Pharmaceutical Co Ltd: cautious scenario ¥3.23, base ¥3.38, optimistic ¥3.53 per share (as of Oct 1, 2026, price ¥11.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688553?
Sichuan Huiyu Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 49.4 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥3.38 is built from several models across several years. Other multiples: P/B 2.1, P/S 7.3, EV/EBITDA 36.4.
How solid is the balance sheet of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
Balance-sheet figures for Sichuan Huiyu Pharmaceutical Co Ltd (as of Oct 1, 2026): return on equity 3.0%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 688553 from its 52-week high?
Sichuan Huiyu Pharmaceutical Co Ltd trades at ¥11.85, about 27% below its 52-week high of ¥16.29 and 20% above the low of ¥9.86 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of ¥3.38 is for.
Which stocks are comparable to Sichuan Huiyu Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sichuan Huiyu Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Oct 1, 2026: price ¥11.85, calculated fair value ¥3.38 (−71%), Quality Score 53/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688553 calculated?
We run Sichuan Huiyu Pharmaceutical Co Ltd through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥3.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.6 % above its aggregate fair value. Sichuan Huiyu Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
The closing price on Oct 9, 2026 was ¥11.85. Our model-based fair value is ¥3.38, about −71% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sichuan Huiyu Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥3.53). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥3.23 to ¥3.53), unusually little disagreement for a valuation.
Key figures of Sichuan Huiyu Pharmaceutical Co Ltd
How large is the market capitalisation of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
The market capitalisation of Sichuan Huiyu Pharmaceutical Co Ltd is 8.0B CNY (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
The price-to-sales ratio of Sichuan Huiyu Pharmaceutical Co Ltd is 7.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
Earnings per share at Sichuan Huiyu Pharmaceutical Co Ltd are ¥0.2400 (price ÷ EPS = P/E 49.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
The dividend yield of Sichuan Huiyu Pharmaceutical Co Ltd is 1.1% (payout 56.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
The net margin of Sichuan Huiyu Pharmaceutical Co Ltd is −2.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
The return on equity (ROE) of Sichuan Huiyu Pharmaceutical Co Ltd is 3.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
On an EBIT basis the return on assets of Sichuan Huiyu Pharmaceutical Co Ltd is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
The operating margin of Sichuan Huiyu Pharmaceutical Co Ltd is 2.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
Revenue at Sichuan Huiyu Pharmaceutical Co Ltd is growing +32.0% versus a year earlier (3y avg −12.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
Earnings per share at Sichuan Huiyu Pharmaceutical Co Ltd are growing −66.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sichuan Huiyu Pharmaceutical Co Ltd (688553) generate?
The free cash flow of Sichuan Huiyu Pharmaceutical Co Ltd is −14.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sichuan Huiyu Pharmaceutical Co Ltd (688553) hold?
Sichuan Huiyu Pharmaceutical Co Ltd holds more cash than debt, 1.7B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sichuan Huiyu Pharmaceutical Co Ltd in the live analysis
One click puts Sichuan Huiyu Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
